Phase II study of perioperative toripalimab in combination with FLOT in patients with locally advanced resectable gastric/gastroesophageal junction (GEJ) adenocarcinoma.

被引：17
|
作者：
Li, Hongli
Deng, Jingyu
Ge, Shaohua
Zang, Fenglin
Zhang, Le
Ren, Peng
Wang, Baogui
Cao, Fuliang
Deng, Ting
Liu, Rui
Ning, Tao
Yang, Yuchong
Bai, Ming
Wang, Xia
Ji, Zhi
Duan, Jingjing
Liu, Yong
Zhou, Dejun
Liang, Han
Ba, Yi
机构：
[1] Tianjin Med Univ Canc Inst & Hosp, Dept Gastrointestinal Med Oncol, Key Lab Canc Prevent & Therapy, Natl Clin Res Ctr Canc,Tianjins Clin Res Ctr Canc, Tianjin, Peoples R China
[2] Tianjin Med Univ Inst & Hop, Dept Gastroenterol Surg Oncol, Tianjin, Peoples R China
[3] Tianjin Med Univ Inst & Hosp, Natl Clin Res Ctr Canc, Key Lab Canc Prevent & Therapy, Dept Gastroenterol,Tianjins Clin Res Ctr Canc, Tianjin, Peoples R China
[4] Tianjin Med Univ Inst & Hop, Dept Pathol, Tianjin, Peoples R China
[5] Tianjin Med Univ Inst & Hop, Dept Esophageal Canc, Tianjin, Peoples R China
[6] Tianjin Med Univ Inst & Hop, Dept Endoscopy, Tianjin, Peoples R China
[7] Tianjin Med Univ Canc Inst & Hosp, Dept Gastrointestinal Med Oncol, Natl Clin Res Ctr Canc, Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China
[8] Tianjins Clin Res Ctr Canc, Tianjin, Peoples R China
[9] Tianjin Med Univ Canc Inst & Hosp, Dept Gastrointestinal Med Oncol, Key Lab Canc Prevent & Therapy, Tianjins Clin Res Ctr Canc,Natl Clin Res Ctr Canc, Tianjin, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.4050
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4050
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Perioperative sintilimab combination with SOX for resectable locally advanced gastric/gastroesophageal junction cancer(GC/GEJC): Initial findings of a single-arm phase II trial
    Ding, Xuewei
    Li, Bin
    Xue, Qiang
    Cai, Mingzhi
    Cui, Jingli
    Wang, Baogui
    Ke, Bin
    Zhang, Rupeng
    Liang, Han
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [42] A phase II study of capecitabine, carboplatin, and bevacizumab for metastatic or unresectable gastroesophageal junction and gastric adenocarcinoma.
    Kunz, Pamela L.
    Nandoskar, Prachi
    Koontz, Michael Zach
    Ji, Hanlee
    Ford, James M.
    Balise, Raymond R.
    Kamaya, Aya
    Rubin, Daniel
    Fisher, George A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [43] A phase Ib/II study of fruquintinib in combination with SOX and toripalimab as first-line treatment for advanced metastatic gastric/gastroesophageal junction adenocarcinoma (GC/GEJC).
    Meng, Xiangrui
    Shan, Zhengzheng
    Guan, Lulu
    Dao, Xin
    Fan, Qingxia
    Wang, Feng
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 335 - 335
  • [44] Phase II trial of surufatinib plus toripalimab for disease progression after first-line chemotherapy with platinum and fluoropyrimidine in advanced gastric or gastroesophageal junction adenocarcinoma.
    Shen, Lin
    Lu, Ming
    Chen, Zhendong
    Ye, Feng
    Zhang, Yanqiao
    Li, Zhiping
    Zhang, Xing
    Yin, Fei
    Chen, Wei
    Sheng, Wang
    Ma, Yue
    Zhao, Yaqin
    Weng, Desheng
    Yin, Xiaolei
    Zhou, Jinghong
    Shi, Haiyan
    Tan, Panfeng
    Su, Weiguo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [45] Analysis of effectiveness of FLOT perioperative chemotherapy in resectable locally advanced gastric or esophago-gastric junction cancer in a Kazakhstani population
    Kerimkulov, Altay
    Sarina, Tomiris
    Uskenbayev, Talgat
    Usipbekov, Bayduysen
    Umerzakova, Bakhtzhan
    Kovalchuk, Dina
    Sipenova, Aigerim
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [46] Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study
    Jiang, Haiping
    Yu, Xiongfei
    Li, Ning
    Kong, Mei
    Ma, Zhimin
    Zhou, Donghui
    Wang, Weibin
    Wang, Haohao
    Wang, Haiyong
    He, Kuifeng
    Li, Zhongqi
    Lu, Yimin
    Zhang, Jing
    Zhao, Kui
    Zhang, Yafei
    Xu, Nong
    Li, Ziran
    Liu, Ying
    Wang, Yan
    Wang, Yisen
    Teng, Lisong
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (03)
  • [47] HER-FLOT: Trastuzumab in combination with FLOT as perioperative treatment for patients with HER2-positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the AIO Gastric Cancer Study Group.
    Hofheinz, Ralf
    Hegewisch-Becker, Susanna
    Thuss-Patience, Peter C.
    Kunzmann, Volker
    Fuchs, Martin
    Graeven, Ullrich
    Homann, Nils
    Heinemann, Volker
    Pohl, Michael
    Tannapfel, Andrea
    Al-Batran, Salah-Eddin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [48] A phase I/IIa open label, nonrandomized, multicenter study of CYNK-101 in combination with trastuzumab and pembrolizumab in patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.
    Gutierrez, Martin
    Sigal, Darren
    Berth, Kevin
    Kuehn, Adam
    Colerangle, John
    Koppisetti, Sharmila
    He, Shawn
    van der Touw, William
    Hariri, Robert
    Awadalla, Mark S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS478 - TPS478
  • [49] Perioperative chemotherapy with docetaxel, oxaliplatin and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): a randomized, multicenter phase 3 trial
    Al-Batran, S. -E.
    Pauligk, C.
    Homann, N.
    Schmalenberg, H.
    Kopp, H. -G.
    Haag, G. M.
    Luley, K. B.
    Schmiegel, W.
    Folprecht, G.
    Probst, S.
    Prasnikar, N.
    Thuss-Patience, P.
    Fischbach, W.
    Trojan, J.
    Koenigsmann, M.
    Goetze, T. O.
    Kraus, T. W.
    Battmann, A.
    Moenig, S. P.
    Bechstein, W.
    Gaiser, T.
    Tannapfel, A.
    Jaeger, E.
    Schuler, M.
    Lindig, U.
    Pohl, M.
    Kasper, S.
    Moehler, M.
    Hofheinz, R. D.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 200 - +
  • [50] KEYNOTE-062:Phase 3 study of pembrolizumab alone or in combination with chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.
    Tabernero, Josep
    Bang, Yung-Jue
    Fuchs, Charles S.
    Ohtsu, Atsushi
    Kher, Uma
    Lam, Baohoang
    Koshiji, Minori
    Van Cutsem, Eric
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345